CN101184494B - 制备和分离磷脂的方法 - Google Patents
制备和分离磷脂的方法 Download PDFInfo
- Publication number
- CN101184494B CN101184494B CN2006800186998A CN200680018699A CN101184494B CN 101184494 B CN101184494 B CN 101184494B CN 2006800186998 A CN2006800186998 A CN 2006800186998A CN 200680018699 A CN200680018699 A CN 200680018699A CN 101184494 B CN101184494 B CN 101184494B
- Authority
- CN
- China
- Prior art keywords
- concentration
- reaction
- enzyme
- add
- phosphatidylcholine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 99
- 150000003904 phospholipids Chemical class 0.000 title claims description 35
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims abstract description 166
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims abstract description 166
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims abstract description 84
- 108090000553 Phospholipase D Proteins 0.000 claims abstract description 39
- 238000002360 preparation method Methods 0.000 claims abstract description 32
- 238000006243 chemical reaction Methods 0.000 claims abstract description 23
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229910044991 metal oxide Inorganic materials 0.000 claims abstract description 9
- 150000004706 metal oxides Chemical class 0.000 claims abstract description 9
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims abstract description 7
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims abstract description 5
- 230000008569 process Effects 0.000 claims abstract description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims abstract description 3
- 125000002252 acyl group Chemical group 0.000 claims abstract description 3
- 150000001342 alkaline earth metals Chemical class 0.000 claims abstract description 3
- 125000005210 alkyl ammonium group Chemical group 0.000 claims abstract description 3
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 57
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 51
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical group CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 45
- 238000000746 purification Methods 0.000 claims description 40
- 239000000243 solution Substances 0.000 claims description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 33
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 25
- 239000003960 organic solvent Substances 0.000 claims description 19
- 108090000790 Enzymes Proteins 0.000 claims description 18
- 102000004190 Enzymes Human genes 0.000 claims description 18
- 239000000872 buffer Substances 0.000 claims description 17
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 14
- 239000006228 supernatant Substances 0.000 claims description 13
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 12
- 239000007795 chemical reaction product Substances 0.000 claims description 12
- 239000011780 sodium chloride Substances 0.000 claims description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 11
- 238000005917 acylation reaction Methods 0.000 claims description 11
- 230000001476 alcoholic effect Effects 0.000 claims description 11
- 239000012528 membrane Substances 0.000 claims description 11
- 239000012429 reaction media Substances 0.000 claims description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 238000000108 ultra-filtration Methods 0.000 claims description 9
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 8
- 230000008859 change Effects 0.000 claims description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 230000003197 catalytic effect Effects 0.000 claims description 6
- 230000014759 maintenance of location Effects 0.000 claims description 6
- 241000936729 Streptomyces hachijoensis Species 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 230000008021 deposition Effects 0.000 claims description 5
- 125000001095 phosphatidyl group Chemical group 0.000 claims description 5
- 239000002798 polar solvent Substances 0.000 claims description 5
- 238000012546 transfer Methods 0.000 claims description 5
- -1 dimethyl sulfoxine Chemical compound 0.000 claims description 4
- 238000000855 fermentation Methods 0.000 claims description 4
- 230000004151 fermentation Effects 0.000 claims description 4
- 244000005700 microbiome Species 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 150000002500 ions Chemical class 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims description 2
- 238000001471 micro-filtration Methods 0.000 claims description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 7
- 239000007864 aqueous solution Substances 0.000 claims 4
- 102100032967 Phospholipase D1 Human genes 0.000 claims 2
- 239000013522 chelant Substances 0.000 claims 2
- 108010002266 phospholipase D1 Proteins 0.000 claims 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 150000008105 phosphatidylcholines Chemical class 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 abstract description 7
- 102000011420 Phospholipase D Human genes 0.000 abstract 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N Calcium oxide Chemical compound [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 27
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 26
- 239000000292 calcium oxide Substances 0.000 description 26
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 25
- 239000012071 phase Substances 0.000 description 18
- 229940088598 enzyme Drugs 0.000 description 15
- 239000000395 magnesium oxide Substances 0.000 description 14
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 14
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 14
- 229960001153 serine Drugs 0.000 description 12
- 239000011787 zinc oxide Substances 0.000 description 12
- 238000000926 separation method Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- 239000008351 acetate buffer Substances 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- 238000006911 enzymatic reaction Methods 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 159000000007 calcium salts Chemical class 0.000 description 4
- 239000003599 detergent Substances 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 239000000010 aprotic solvent Substances 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- AMWRITDGCCNYAT-UHFFFAOYSA-L hydroxy(oxo)manganese;manganese Chemical compound [Mn].O[Mn]=O.O[Mn]=O AMWRITDGCCNYAT-UHFFFAOYSA-L 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 230000006886 spatial memory Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 description 1
- 239000005751 Copper oxide Substances 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 208000035126 Facies Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 150000008550 L-serines Chemical class 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 102000011759 adducin Human genes 0.000 description 1
- 108010076723 adducin Proteins 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000000823 artificial membrane Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229910000428 cobalt oxide Inorganic materials 0.000 description 1
- IVMYJDGYRUAWML-UHFFFAOYSA-N cobalt(ii) oxide Chemical compound [Co]=O IVMYJDGYRUAWML-UHFFFAOYSA-N 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229910000431 copper oxide Inorganic materials 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 239000012540 ion exchange chromatography resin Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229940087562 sodium acetate trihydrate Drugs 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 239000008348 synthetic phosphatidyl choline Substances 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J7/00—Phosphatide compositions for foodstuffs, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/06—Alanine; Leucine; Isoleucine; Serine; Homoserine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P9/00—Preparation of organic compounds containing a metal or atom other than H, N, C, O, S or halogen
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Birds (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000164A ITPD20050164A1 (it) | 2005-05-30 | 2005-05-30 | Processo per la preparazione e l'isolamento di fosfatidi |
| ITPD2005A000164 | 2005-05-30 | ||
| US70387005P | 2005-08-01 | 2005-08-01 | |
| US60/703,870 | 2005-08-01 | ||
| PCT/EP2006/005030 WO2006128639A2 (en) | 2005-05-30 | 2006-05-26 | Process for the preparation and isolation of phosphatides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101184494A CN101184494A (zh) | 2008-05-21 |
| CN101184494B true CN101184494B (zh) | 2012-03-21 |
Family
ID=39449427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2006800186998A Expired - Fee Related CN101184494B (zh) | 2005-05-30 | 2006-05-26 | 制备和分离磷脂的方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7759095B2 (ja) |
| EP (2) | EP2431020B1 (ja) |
| JP (1) | JP5113042B2 (ja) |
| KR (1) | KR101298560B1 (ja) |
| CN (1) | CN101184494B (ja) |
| AT (1) | ATE546145T1 (ja) |
| AU (1) | AU2006254376B2 (ja) |
| BR (1) | BRPI0611316B8 (ja) |
| CA (1) | CA2610575C (ja) |
| ES (2) | ES2382748T3 (ja) |
| HK (1) | HK1119584A1 (ja) |
| IL (1) | IL187749A (ja) |
| IT (1) | ITPD20050164A1 (ja) |
| MX (1) | MX2007015064A (ja) |
| NO (1) | NO337009B1 (ja) |
| PL (2) | PL2431020T3 (ja) |
| PT (2) | PT2431020E (ja) |
| WO (1) | WO2006128639A2 (ja) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITPD20050164A1 (it) | 2005-05-30 | 2006-11-30 | Fidia Farmaceutici | Processo per la preparazione e l'isolamento di fosfatidi |
| HUE043241T2 (hu) | 2007-06-05 | 2019-08-28 | Bank Of Canada | Tinta- vagy festékkészítmények, eljárások alkalmazásukra és azokból származó termékek |
| CN102439125B (zh) * | 2010-12-03 | 2014-04-30 | 上海赢贝生物技术有限公司 | 一种制备富含多不饱和双键脂肪酰基的磷脂酰丝氨酸的高品质南极磷虾油的方法 |
| CN102485899A (zh) * | 2010-12-03 | 2012-06-06 | 张永志 | 一种制备富含多不饱和双键脂肪酰基的磷脂酰丝氨酸的高品质南极磷虾油的方法 |
| ITPD20120021A1 (it) | 2012-01-26 | 2013-07-27 | Fidia Farmaceutici | "nuove composizioni farmaceutiche contenenti fosfatidilserina e curcumina". |
| CN104327114A (zh) * | 2014-11-06 | 2015-02-04 | 江南大学 | 一种磷脂酰丝氨酸的制备方法 |
| CN112352051A (zh) * | 2019-12-31 | 2021-02-09 | 邦泰生物工程(深圳)有限公司 | 一种提高磷脂酶d转脂活性的方法以及用其生产磷脂酰丝氨酸的方法 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0711559A2 (en) * | 1994-11-08 | 1996-05-15 | Kabushiki Kaisha Yakult Honsha | Use of phosphatidylserines for the manufacture of a medicament for improving cerebration |
| US20030124160A1 (en) * | 2001-10-12 | 2003-07-03 | Petrescu Stefana M. | Targeted drug delivery |
| WO2003088761A2 (de) * | 2002-04-19 | 2003-10-30 | Bioghurt Biogarde Gmbh & Co. Kg | Physiologisch verträgliche, phospholipid-haltige, stabile und harte matrix |
| US20040235795A1 (en) * | 2001-10-05 | 2004-11-25 | Ralf Jager | Utilization of phosphatidylserine in the treatment of attention deficit syndrome (adhs) |
| US20040235119A1 (en) * | 2001-08-28 | 2004-11-25 | Hans-Ulrich Hoppe | Method for the production of phospholipids |
| WO2005023271A1 (de) * | 2003-09-04 | 2005-03-17 | Bioghurt Biogarde Gmbh & Co. Kg | Physiologisch aktive zusammensetzung auf phosphatidylserin-basis |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3869482A (en) * | 1972-07-31 | 1975-03-04 | Etapharm Chem Pharm Lab G M B | Method of producing highly purified phosphatides |
| AT315359B (de) * | 1972-07-31 | 1974-05-27 | Etapharm Chem Pharm Lab Ges M | Verfahren zur Herstellung von hochgereinigten Phosphatiden aus tierischen Organen |
| JPS63245684A (ja) * | 1987-03-31 | 1988-10-12 | Japanese Res & Dev Assoc Bio Reactor Syst Food Ind | ホスフアチジン酸誘導体の製造法 |
| US5183750A (en) * | 1989-05-26 | 1993-02-02 | Kao Corporation | Processes for the production of phosphatidic acid |
| IT1260149B (it) * | 1992-04-17 | 1996-03-28 | Fidia Spa | Metodo per la preparazione e purificazione di miscele di fosfolipidi prive di contaminanti da virus non convenzionali |
| US5700668A (en) | 1995-12-08 | 1997-12-23 | Italfarmaco Sud S.P.A. | Process for the industrial preparation of phosphatidylserine |
| DE19917249C2 (de) | 1999-02-26 | 2001-09-27 | Meyer Lucas Gmbh & Co | Verfahren zur Herstellung von Phosphatidylserin-Produkten |
| IT1311929B1 (it) | 1999-04-28 | 2002-03-20 | Chemi Spa | Procedimento per la preparazione di fosfatidilserine. |
| DE19926770A1 (de) | 1999-06-11 | 2000-12-14 | Basf Ag | Nukleinsäurefragment und Vektor, enthaltend eine Halogenase, sowie ein Verfahren zur Halogenierung chemischer Verbindungen |
| EP1190041B1 (en) * | 1999-06-15 | 2005-01-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Enzymatic preparation of phospholipids in aqueous media |
| AU2001261647A1 (en) | 2000-05-15 | 2001-11-26 | Identix Incorporated | Fingerprint imaging device |
| JP4298902B2 (ja) | 2000-08-09 | 2009-07-22 | 株式会社ヤクルト本社 | リン脂質の製造法 |
| IT1319679B1 (it) | 2000-12-05 | 2003-10-23 | Chemi Spa | Processo di purificazione di fosfatidilserina. |
| ITPD20010031A1 (it) | 2001-02-09 | 2002-08-09 | Fidia Farmaceutici | Procedimento per la preparazione di fosfatidi puri e loro impiego in campo cosmetico, farmaceutico ed alimentare. |
| DE102004002053A1 (de) * | 2004-01-15 | 2005-08-04 | Bioghurt Biogarde Gmbh & Co. Kg | Verfahren zur Herstellung von Phosphatidylserin und dessen Reinigung durch Extraktion |
| ITPD20050164A1 (it) | 2005-05-30 | 2006-11-30 | Fidia Farmaceutici | Processo per la preparazione e l'isolamento di fosfatidi |
-
2005
- 2005-05-30 IT IT000164A patent/ITPD20050164A1/it unknown
-
2006
- 2006-05-26 PL PL11171047T patent/PL2431020T3/pl unknown
- 2006-05-26 KR KR1020077027896A patent/KR101298560B1/ko active IP Right Grant
- 2006-05-26 ES ES06753893T patent/ES2382748T3/es active Active
- 2006-05-26 WO PCT/EP2006/005030 patent/WO2006128639A2/en not_active Application Discontinuation
- 2006-05-26 CA CA2610575A patent/CA2610575C/en not_active Expired - Fee Related
- 2006-05-26 PT PT111710471T patent/PT2431020E/pt unknown
- 2006-05-26 BR BRPI0611316A patent/BRPI0611316B8/pt not_active IP Right Cessation
- 2006-05-26 AT AT06753893T patent/ATE546145T1/de active
- 2006-05-26 PL PL06753893T patent/PL1890706T3/pl unknown
- 2006-05-26 EP EP11171047.1A patent/EP2431020B1/en active Active
- 2006-05-26 EP EP06753893A patent/EP1890706B1/en active Active
- 2006-05-26 AU AU2006254376A patent/AU2006254376B2/en not_active Ceased
- 2006-05-26 PT PT06753893T patent/PT1890706E/pt unknown
- 2006-05-26 MX MX2007015064A patent/MX2007015064A/es active IP Right Grant
- 2006-05-26 JP JP2008513987A patent/JP5113042B2/ja not_active Expired - Fee Related
- 2006-05-26 US US11/922,680 patent/US7759095B2/en active Active
- 2006-05-26 ES ES11171047.1T patent/ES2501015T3/es active Active
- 2006-05-26 CN CN2006800186998A patent/CN101184494B/zh not_active Expired - Fee Related
-
2007
- 2007-11-29 NO NO20076158A patent/NO337009B1/no not_active IP Right Cessation
- 2007-11-29 IL IL187749A patent/IL187749A/en active IP Right Grant
-
2008
- 2008-10-28 HK HK08111830.3A patent/HK1119584A1/xx not_active IP Right Cessation
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0711559A2 (en) * | 1994-11-08 | 1996-05-15 | Kabushiki Kaisha Yakult Honsha | Use of phosphatidylserines for the manufacture of a medicament for improving cerebration |
| US20040235119A1 (en) * | 2001-08-28 | 2004-11-25 | Hans-Ulrich Hoppe | Method for the production of phospholipids |
| US20040235795A1 (en) * | 2001-10-05 | 2004-11-25 | Ralf Jager | Utilization of phosphatidylserine in the treatment of attention deficit syndrome (adhs) |
| US20030124160A1 (en) * | 2001-10-12 | 2003-07-03 | Petrescu Stefana M. | Targeted drug delivery |
| WO2003088761A2 (de) * | 2002-04-19 | 2003-10-30 | Bioghurt Biogarde Gmbh & Co. Kg | Physiologisch verträgliche, phospholipid-haltige, stabile und harte matrix |
| WO2005023271A1 (de) * | 2003-09-04 | 2005-03-17 | Bioghurt Biogarde Gmbh & Co. Kg | Physiologisch aktive zusammensetzung auf phosphatidylserin-basis |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101184494B (zh) | 制备和分离磷脂的方法 | |
| JP4792154B2 (ja) | ホスファチジルセリンの製造方法 | |
| JPH09173092A (ja) | ホスファチジルセリンの工業的製造方法 | |
| WO2009154309A1 (ja) | 高純度リン脂質の製造方法およびその方法で得られた高純度のスフィンゴミエリンとプラズマローゲン型グリセロリン脂質 | |
| CN103338659A (zh) | 酵母抽提物的提取残渣的利用方法 | |
| CN104818303A (zh) | 一种酶法制备甘油磷酸胆碱的方法 | |
| US5100787A (en) | Method for preparing highly purified phosphatidylinositol | |
| JP3032357B2 (ja) | リン脂質画分の分画精製方法 | |
| US6878532B1 (en) | Method of producing phosphatidylserine | |
| JP5526467B2 (ja) | セラミドの製造方法 | |
| JPS63123389A (ja) | 酵素法リン脂質−ｄ−セリン誘導体の製造法 | |
| JP2002241385A (ja) | ホスファチジルセリンの分画法 | |
| KR102433277B1 (ko) | 유지를 이용한 콜린알포세레이트 조성물의 제조 방법 | |
| JP7222551B2 (ja) | 環状ホスファチジン酸ナトリウムの製造方法 | |
| RU2482186C2 (ru) | Способ получения фосфатидилсерина | |
| JP2008061546A (ja) | ホスファチジルイノシトールの製造方法 | |
| JPH07265089A (ja) | 魚介類からのセラミドの製造方法 | |
| JP2005261388A (ja) | リゾホスファチジルグリセロールの製造方法 | |
| JPH03206891A (ja) | 高度不飽和脂肪酸の分取方法 | |
| WU et al. | Research survey and prospect on comprehensive processing of rapeseed | |
| JP2000080395A (ja) | スフィンゴ脂質の製造法 | |
| JPH06253874A (ja) | リン脂質の製造法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1119584 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1119584 Country of ref document: HK |
|
| C56 | Change in the name or address of the patentee |
Owner name: FIDIA PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: FIDIA FARMACEUTICI |
|
| CP01 | Change in the name or title of a patent holder |
Address after: Italy Habas Hotel Patentee after: FIDIA FARMACEUTICI S.P.A. Address before: Italy Habas Hotel Patentee before: FIDIA FARMACEUTICI S.P.A. |
|
| CP01 | Change in the name or title of a patent holder | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120321 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |